Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Jan 8;30(2):519–530. doi: 10.1038/s41591-023-02758-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024, corrected publication 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a, Percentage of pathologic regression shown per tumor. The black horizontal line depicts the demarcation for MPRs corresponding to 90% tumor regression. The dashed line demarcates PR (50% tumor regression). Colors of the bars represent different Lauren subtypes, the asterisks below bars indicate dMMR tumors, and the hash (#) indicates the patient with a pCR in the primary tumor but <1% RVT in lymph nodes. b, Kaplan–Meier plot of DFS for pathologic responders (red) versus nonresponders (blue) in patients evaluable for response in the PANDA trial. c, Posttreatment resection specimen from a patient with a pMMR GEJ tumor (cT3N1) who had a pCR. H&E stain showing normal mucosa (M) and complete regression of the adenocarcinoma, which was characterized by mucin lakes (star) and tertiary lymphoid structures (arrowheads). d, Posttreatment H&E stains of a resected lymph node from a patient with pretreatment clinical N3 stage. Left, some preexistent lymphoid tissue (arrowheads) and complete tumor regression characterized by cholesterol clefts (circle). Right, multinucleated giant cells (arrowheads).